Immune System Engineering For Targeted Tolerance in Type 1 Diabetes (R01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

Type 1 diabetes (T1D) results in part from the autoimmune-mediated dysfunction or destruction of insulin-producing pancreatic beta cells. This funding opportunity is for projects that seek to discover ways to change the course of the disease by directly establishing tolerance. Immune responses could be engineered for tolerance induction through the manipulation of antigens, cells, or cellular microenvironments. Collaborations between T1D experts and investigators from other fields, including (but not limited to) cancer immunology and biomaterials engineering, are especially encouraged.


  • Letter of Intent Due Date(s): April 10, 2018 and November 6, 2018
  • Application Due Date(s): May 10, 2018 and December 6, 2018

RFA-DK-17-020 Expiration Date December 7, 2018

Agency Website



Amount Description

Application budgets are limited to $300,000 direct costs per year.

The maximum project period is 5 years.

    Funding Type





    Medical - Basic Science
    Medical - Clinical Science
    Medical - Translational

    External Deadline

    December 6, 2018